Randomized Study of Noninferiority Comparing Prosthetic and Autologous Vein Above-Knee Femoropopliteal Bypasses

Midy, D.; Papon, X.; Patra, P.; Kodja, Réda Hassen; Feugier, Patrick; Plissonnier, Didier; Reix, Thierry; Chêne, Geneviève; Bérard, Xavier; Habozit, B.; Becquemin, J. P.; Rosset, Eugénio; Magnan, Pierre Édouard

doi:10.1016/j.avsg.2015.07.047

Cited by 13 publications

(25 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After 12 months the primary patency was 73.2%. In a study by Midy et al, 11 the authors compared the efficacy of prosthetic and autologous vein for above-the-knee femoropopliteal bypasses. With 5-year secondary patency rates of 84.6% and 70.8% for the prosthetic group and autologous vein group, respectively, they concluded that there was no significant difference between the treatment modalities.…”

Section: Discussionmentioning

confidence: 99%

ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions

et al. 2020

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A noninferiority RCT by Midy et al 1 ) included patients who underwent above-knee femoropopliteal bypass using either autologous vein ( n = 44) or polyester or expanded polytetrafluoroethylene (PTFE) graft ( n = 52). Although recruitment could not reach the required numbers, the patency rate in the prosthetic group was nevertheless higher than that obtained in the autologous vein group, whatever the type of analysis carried out.…”

Section: Appraisal Of Aha/acc Guideline Statements and The Appadc Recmentioning

confidence: 99%

Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee

Abola

Golledge

Miyata

et al. 2020

JAT

View full text Add to dashboard Cite

Background: Peripheral artery disease (PAD) is the most underdiagnosed, underestimated and undertreated of the atherosclerotic vascular diseases despite its poor prognosis. There may be racial or contextual differences in the Asia-Pacific region as to epidemiology, availability of diagnostic and therapeutic modalities, and even patient treatment response. The Asian Pacific Society of Atherosclerosis and Vascular Diseases (APSAVD) thus coordinated the development of an Asia-Pacific Consensus Statement (APCS) on the Management of PAD. Objectives: The APSAVD aimed to accomplish the following: 1) determine the applicability of the 2016 AHA/ ACC guidelines on the Management of Patients with Lower Extremity Peripheral Artery Disease to the Asia-Pacific region; 2) review Asia-Pacific literature; and 3) increase the awareness of PAD. Methodology: A Steering Committee was organized to oversee development of the APCS, appoint a Technical Working Group (TWG) and Consensus Panel (CP). The TWG appraised the relevance of the 2016 AHA/ACC PAD Guideline and proposed recommendations which were reviewed by the CP using a modified Delphi technique. Results: A total of 91 recommendations were generated covering history and physical examination, diagnosis, and treatment of PAD-3 new recommendations, 31 adaptations and 57 adopted statements. This Asia-Pacific Consensus Statement on the Management of PAD constitutes the first for the Asia-Pacific Region. It is intended for use by health practitioners involved in preventing, diagnosing and treating patients with PAD and ultimately the patients and their families themselves.

show abstract

“…Our database search (see PRISMA flow diagram; Figure 1) identified 10 RCTs, 8 –12,17 –21 2 of which had to be excluded. Klinkert et al 17 and Burger et al 18 both used the same patient cohort: Burger et al 18 was a 2-year study, whereas Klinkert et al 17 followed up the patients for 5 years; therefore, the former was excluded.…”

Section: Resultsmentioning

confidence: 99%

“…Some of the earlier work 6,7 involving prosthetic grafts yielded promising results and this saw a rise in their use, which went on to be supported by prospective trials that showed comparable results with vein grafts. 8 –12 Arguments supporting the use of prosthetic grafts include shorter operating time, reduction in the amount of tissue dissection, and also preservation of the saphenous vein, which can then be used if subsequent lower limb arterial reconstruction or coronary artery bypass grafting is needed. 13…”

Section: Introductionmentioning

confidence: 99%

Vein Versus Prosthetic Graft for Femoropopliteal Bypass Above the Knee: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Sharrock

Antoniou

2019

Angiology

View full text Add to dashboard Cite

Conflicting evidence exists surrounding which conduit material is preferable in above-knee femoropopliteal bypass surgery. We performed a systemic review of electronic information sources to identify randomized controlled trials (RCTs) comparing vein versus prosthetic grafts in above-knee femoropopliteal bypasses. Eight RCTs reporting 1271 grafts (608 saphenous vein and 663 prosthetic) in 1132 patients were included. At 5 years, the vein group had significantly higher primary patency (odds ratio [OR]: 1.73, 95% confidence interval [CI]: 1.17-2.55, P = 0.006), primary assisted patency (OR: 4.02, 95% CI: 2.84-5.70, P < 0.0001), and secondary patency (OR: 1.83, 95% CI: 1.20-2.80, P = 0.005) rates compared with the prosthetic group. The vein group required significantly fewer reinterventions (OR: 0.33, 95% CI: 0.18-0.60, P = 0.0003). There was no significant difference in 30-day mortality (risk difference: −0.01, 95% CI: −0.02 to 0.01, P = 0.34), 30-day morbidity (OR: 1.58, 95% CI: 0.61-4.06, P = 0.35), major amputation (OR: 0.71, 95% CI: 0.43-1.18, P = 0.19), or overall survival (OR: 0.95, 95% CI: 0.70-1.30, P = 0.76) when comparing vein versus prosthetic grafts. Our analysis supports the use of the saphenous vein in above-knee femoropopliteal bypass grafting owing to its superiority in primary, primary assisted, and secondary patency rates and less need for reintervention when compared with prosthetic grafts.

show abstract

Randomized Study of Noninferiority Comparing Prosthetic and Autologous Vein Above-Knee Femoropopliteal Bypasses

Cited by 13 publications

References 16 publications

ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions

ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions

Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease: A Report from the Asian Pacific Society of Atherosclerosis and Vascular Disease Asia-Pacific Peripheral Artery Disease Consensus Statement Project Committee

Vein Versus Prosthetic Graft for Femoropopliteal Bypass Above the Knee: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Contact Info

Product

Resources

About